History of Changes for Study: NCT03625037

Version	Submitted Date	Changes
1	August 9, 2018	None (earliest Version on record)
2	August 14, 2018	Study Status
3	September 13, 2018	Study Status and Contacts/Locations
4	September 27, 2018	Contacts/Locations and Study Status
5	January 7, 2019	Contacts/Locations, Study Status and Eligibility
6	January 14, 2019	Contacts/Locations and Study Status
7	February 26, 2019	Contacts/Locations and Study Status
8	April 12, 2019	Study Status and Contacts/Locations
9	July 19, 2019	Study Status and Contacts/Locations
10	August 20, 2020	Contacts/Locations, Arms and Interventions, Outcome Measures, Study Design, Study Description, Study Status, Eligibility and Sponsor/Collaborators
11	January 8, 2021	Contacts/Locations, Study Status and Study Design
12	February 11, 2021	Contacts/Locations, Study Status, Study Identification, Eligibility and Study Design
13	July 27, 2021	Study Status and Contacts/Locations
14	June 17, 2022	Outcome Measures, Contacts/Locations, Arms and Interventions, Study Status, Study Description, Eligibility and Study Identification
15	October 18, 2022	Outcome Measures, Study Description, Study Status, Study Identification, Contacts/Locations, Eligibility and Study Design
16	February 7, 2023	Study Status
17	February 23, 2023	Study Status
18	March 27, 2023	Outcome Measures, Study Status, Study Identification, Study Description, Eligibility and Conditions
19	May 25, 2023	Study Status, References, Arms and Interventions and Study Description
20	May 30, 2023	Study Status and Study Identification
21	June 27, 2023	Study Status, Contacts/Locations and Study Design
22	August 7, 2023	Contacts/Locations, Study Status and Study Identification
23	January 2, 2024	Study Status
24	February 14, 2024	Outcome Measures, Contacts/Locations, Study Description, Study Status, Eligibility, Arms and Interventions, Study Design and Conditions
25	March 4, 2024	Study Status and Study Identification
26	March 25, 2024	Recruitment Status, Study Status, Contacts/Locations and Study Design
27	April 4, 2024	Study Status
28	May 6, 2024	Study Status and Study Identification

Brief Summary:

The purpose of this trial is to measure the following in participants with relapsed and/or refractory B-cell lymphoma who receive epcoritamab, an antibody also known as EPKINLY™ and GEN3013 (DuoBody®-CD3xCD20):

The dose schedule for epcoritamab
The side effects seen with epcoritamab
What the body does with epcoritamab once it is administered
What epcoritamab does to the body once it is administered
How well epcoritamab works against relapsed and/or refractory B-cell lymphoma

The trial consists of 3 parts:

a dose-escalation part [Phase 1, first-in-human (FIH)]
an expansion part (Phase 2a)
a dose-optimization part (OPT) (Phase 2a)

The trial time for each participant depends on which trial part the participant enters:

For the dose-escalation part, each participant will be in the trial for approximately 1 year, which is made up of 21 days of screening, 6 months of treatment (the total time of treatment may be different for each participant), and 6 months of follow-up (the total time of follow-up may be different for each participant).
For the expansion and dose-OPT parts, each participant will be in the trial for approximately 1.5 years, which is made up of 21 days of screening, 1 year of treatment (the total time of treatment may be different for each participant), and 6 months of follow-up (the total time of follow-up may be different for each participant).

Participation in the study will require visits to the sites. During the first month, participants must visit every day or every few days, depending on which trial part the participant enters. After that, participants must visit weekly, every other week, once a month, and once every 2 months, as trial participation ends.

All participants will receive active drug, and no participants will be given placebo.

Detailed Description:

The purpose of the dose-escalation part of the trial is to determine the maximum tolerated dose (MTD) and the recommended Phase 2 dose (RP2D), as well as to establish the safety profile of epcoritamab in participants with relapsed or refractory B-cell lymphoma.

In the expansion part, additional participants will be treated with epcoritamab, at the RP2D and the purpose is to further explore and determine the safety and efficacy of epcoritamab.

The dose-OPT part will evaluate alternative priming and intermediate dose regimens of epcoritamab in participants with:

Diffuse large B-cell lymphoma (DLBCL)
Follicular lymphoma (FL)
Mantle cell lymphoma (MCL)

All participants will receive epcoritamab at the RP2D.

Outcome Measures


Primary Outcome Measures:
1.	Dose-Escalation: Dose Limiting Toxicity (DLT) [ Time Frame: During the first cycle (28 days) in each Dose-OPT Part DLBCL, FL and MCL ] To determine the MTD and/or RP2D to be studied in the Expansion part. DLT will be graded according to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0.
2.	Dose-Escalation: Number of Participants with Adverse Events (AEs) [ Time Frame: From first dose until the end of the safety follow-up period (Up to 1 year) ] An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.
3.	Expansion and Dose-OPT MCL: Overall Response Rate (ORR) [ Time Frame: Up to 1.5 years ] ORR is defined as the percentage of participants achieving complete response (CR) or partial response (PR) based on Lugano criteria as assessed by independent review committee (IRC).
4.	Dose-OPT DLBCL, FL and MCL: Percentage of Participants with =>Grade 2 Cytokine Release Syndrome (CRS) Events and All Grade CRS Events [ Time Frame: From first dose until 7 days after second full dose (Day 28 for DLBCL; Day 35 for FL; Day 28-35 for MCL) ] CRS will be graded based on American Society for Transplantation and Cellular Therapy (ASTCT) criteria.
Secondary Outcome Measures:
1.	Dose-Escalation: Number of Participants with Anti-lymphoma Activity of Epcoritamab [ Time Frame: Up to 1 year ] Anti-lymphoma activity will be evaluated as number of participants with resolution of constitutional symptoms, reduction in tumor size, objective, and best response (ORR, CR and PR).
2.	Dose-Escalation: DOR [ Time Frame: Up to 1 year ] DOR is defined as the time from the first documentation of response (CR or PR) to the date of PD or death, whichever occurs earlier as assessed by the investigator.
3.	Expansion: DOR [ Time Frame: Up to 1.5 years ] DOR is defined as the time from the first documentation of response (CR or PR) to the date of PD or death, whichever occurs earlier based on Lugano criteria assessed by IRC.
4.	Expansion Part: Changes in Lymphoma Symptoms as Measured by the Functional Assessment of Cancer Therapy - Lymphoma (FACT-Lym) [ Time Frame: Up to 1.5 year ] Change from baseline in health-related quality of life over time and in relation to treatment will be evaluated using FACT-Lym scale.
5.	Dose-OPT DLBCL and FL: Percentage of Participants with >=Grade 2 CRS Events and All Grade CRS Events Following First Full Dose [ Time Frame: Up to 1.5 years ] CRS will be graded based on ASTCT criteria.
6.	Dose-OPT DLBCL and FL: Percentage of Participants with >=Grade 2 CRS Events and All Grade CRS Events Overall [ Time Frame: Up to 1.5 years ] CRS will be graded based on ASTCT criteria.
7.	Dose-OPT DLBCL and FL: ORR [ Time Frame: Up to 1.5 years ] ORR is defined as the percentage of participants achieving CR or PR assessed by investigator.
8.	Dose-OPT DLBCL and FL: CR Rate [ Time Frame: Up to 1.5 years ] CR rate is defined as the percentage of participants with CR assessed by investigator.
9.	Dose-OPT DLBCL and FL: Duration of CR (DoCR) [ Time Frame: Up to 1.5 years ] DoCR is defined as the time from the first documentation of CR to the date of PD or death, whichever occurs earlier assessed by investigator.
10.	Dose-OPT DLBCL and FL: Progression-Free Survival (PFS) [ Time Frame: Up to 1.5 years ] PFS is defined as the time from Day 1 of Cycle 1 to first documented PD or death due to any cause, whichever occurs earlier assessed by investigator.
11.	Dose-OPT DLBCL and FL: DLT [ Time Frame: During the first cycle (28 days) in each Dose-OPT Part (DLBCL, FL and MCL) ] To determine the MTD and/or RP2D to be studied in the expansion part. DLT will be graded according to NCI-CTCAE version 5.0.
12.	Dose-OPT MCL: Time to Complete Response (TTCR) [ Time Frame: Up to 1.5 years ] TTCR is defined as the time from Day 1 of Cycle 1 to first documentation of complete response based on Lugano criteria and LYRIC as assessed by IRC.
13.	Dose-OPT DLBCL, FL and MCL: DOR [ Time Frame: Up to 1.5 years ] DOR is defined as the time from the first documentation of response (CR or PR) to the date of PD or death, whichever occurs earlier based on Lugano criteria assessed by investigator.
14.	Dose-Escalation and Dose-OPT DLBCL, FL and MCL: Pre-dose Values of Epcoritamab [ Time Frame: Predose and postdose at multiple timepoints of each Cycle (Cycle length=28 days) ]
15.	Dose-Escalation, Expansion Part and Dose-OPT MCL: PFS [ Time Frame: Dose-Escalation: Up to 1 year; Expansion and Dose-OPT Part (MCL): 1.5 years ] PFS is defined as the time from Day 1 of Cycle 1 to first documented PD or death due to any cause, whichever occurs earlier based on Lugano criteria assessed by IRC.
16.	Expansion and Dose-OPT MCL: CR Rate [ Time Frame: Up to 1.5 years ] CR rate is defined as the percentage of participants with CR based on Lugano criteria as assessed by IRC.
17.	Expansion and Dose-OPT MCL: DoCR [ Time Frame: Up to 1.5 years ] DoCR is defined as the time from the first documentation of CR to the date of PD or death, whichever occurs earlier based on Lugano criteria as assessed by IRC.
18.	Expansion and Dose-OPT MCL: ORR [ Time Frame: Up to 1.5 years ] ORR is defined as the percentage of participants achieving CR or PR based on lymphoma response to immunomodulatory therapy criteria (LYRIC) as assessed by IRC.
19.	Expansion and Dose-OPT MCL: Time to Response (TTR) [ Time Frame: Up to 1.5 years ] TTR is defined as the time from Day 1 of Cycle 1 to first documentation of objective tumor response (PR or better) earlier based on Lugano criteria as assessed by IRC.
20.	Expansion and Dose-OPT MCL: CR Rate [ Time Frame: Up to 1.5 years ] CR rate is defined as the percentage of participants with CR based on LYRIC as assessed by IRC.
21.	Expansion and Dose-OPT MCL: PFS [ Time Frame: Up to 1.5 years ] PFS is defined as the time from Day 1 of Cycle 1 to first documented PD or death due to any cause, whichever occurs earlier based on LYRIC assessed by IRC.
22.	Expansion and Dose-OPT MCL: DOR [ Time Frame: Up to 1.5 years ] DOR is defined as the time from the first documentation of response (CR or PR) to the date of PD or death, whichever occurs earlier based on LYRIC assessed by IRC.
23.	Expansion and Dose-OPT MCL: DoCR [ Time Frame: Up to 1.5 years ] DoCR is defined as the time from the first documentation of CR to the date of PD or death, whichever occurs earlier based on LYRIC as assessed by IRC.
24.	Expansion and Dose-OPT MCL: TTR [ Time Frame: Up to 1.5 years ] TTR is defined as the time from Day 1 of Cycle 1 to first documentation of objective tumor response (PR or better) earlier based on LYRIC as assessed by IRC.
25.	Expansion and Dose-OPT DLBCL, FL and MCL: Number of Participants with AEs [ Time Frame: Up to 7 years and 6 months ] An AE is any untoward medical occurrence in a clinical trial participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding), symptom, or disease (new or exacerbated) temporally associated with the use of a medicinal product.
26.	Expansion and Dose-OPT DLBCL, FL and MCL: Rate of Minimal Residual Disease (MRD) Negativity [ Time Frame: Up to 1.5 years ] MRD is defined as percentage of participants with at least 1 MRD negative result.
27.	All Parts: Number of Participants with CRS Events [ Time Frame: Up to Day 1 of Cycle 12 (Cycle length=28 days) ] CRS will be graded based on ASTCT criteria.
28.	All Parts: Immunophenotyping for Absolute T-cell and B-cell [ Time Frame: Up to Day 1 of Cycle 12 (Cycle length=28 days) ] Number of cells will be reported for absolute T-cells and B-cells.
29.	All Parts: T-Cell Activation and Exhaustion Marker [ Time Frame: Up to 7 years and 6 months ] T-Cell Activation and Exhaustion Marker (CD69, CD25, and PD-1) will be measured using flow cytometry.
30.	All Parts: Total Body Clearance of Epcoritamab from the Plasma (CL) [ Time Frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=28 days) ]
31.	All Parts: Area under Curve (AUC) of Epcoritamab [ Time Frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=28 days) ]
32.	All Parts: Maximum (peak) Plasma Concentration (Cmax) of Epcoritamab [ Time Frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=28 days) ]
33.	All Parts: Time to Reach Cmax of Epcoritamab [ Time Frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=28 days) ]
34.	All Parts: Half Life of Epcoritamab (t1/2) [ Time Frame: Predose and postdose at multiple timepoints of each cycle (Cycle length=28 days) ]
35.	All Parts: Number of Participants with Anti-drug Antibody (ADA) [ Time Frame: Up to 7 years and 6 months ] Plasma samples will be screened for antibodies binding to epcoritamab, and for confirmed positive samples, the titer against the two specific arms of epcoritamab will be reported.
36.	All Parts: Time to Next Anti-lymphoma Therapy (TTNT) [ Time Frame: Dose-Escalation: Up to 1 year; Expansion and Dose-OPT Part (DLBCL, FL and MCL): Up to 1.5 years ] TTNT is defined as the time from Day 1 of Cycle 1 to first recorded administration of subsequent anti-lymphoma therapy or death due to any cause, whichever occurs earlier.
37.	All Parts: Overall survival (OS) [ Time Frame: Dose-Escalation: Up to 1 year; Expansion and Dose-OPT Part DLBCL, FL and MCL: Up to 1.5 years ] OS is defined as the time from Day 1 of Cycle 1 to death.

Minimum Age:

18 Years

Maximum Age:

Sex:

All

Gender Based:

Accepts Healthy Volunteers:

Criteria:

Main Inclusion Criteria - Escalation Part (recruitment completed)

Documented CD20+ mature B-cell neoplasm
1. DLBCL - de novo or transformed
2. HGBCL
3. PMBCL
4. FL
5. MCL
6. SLL
7. MZL (nodal, extranodal or mucosa associated)
Relapsed and/or refractory disease following treatment with an anti-CD20 monoclonal antibody (e.g. rituximab) potentially in combination with chemotherapy and/or relapsed after autologous stem cell rescue.
Eastern Cooperative Oncology Group (ECOG) performance status 0,1 or 2.
Participants must have measurable disease by CT, MRI or Positron emission tomography-Computed tomography (PET-CT) scan
Acceptable renal function.
Acceptable liver function.

Main Inclusion Criteria - Expansion & Dose-OPT Parts

Documented CD20 positive mature B cell neoplasm or CD20+ MCL.
DLBCL, de novo or transformed (including double hit or triple hit).
PMBCL
FL grade 3B
Histologic confirmed FL
MZL
SLL
MCL (prior BTKi or intolerant to BTKi)
At least 2 therapies including an anti-CD20 monoclonal antibody containing chemotherapy combination regimen.
Either failed prior autologous hematopoietic stem cell transplantation (HSCT) or ineligible for autologous stem cell transplantation due to age or comorbidities.
At least 1 measurable site of disease based on CT, MRI or PET-CT scan with involvement of 2 or more clearly demarcated lesions and or nodes.

Main Exclusion Criteria - All Parts

Primary central nervous system (CNS) lymphoma or CNS involvement by lymphoma at screening.
Known past or current malignancy other than inclusion diagnosis.
AST, and/or ALT >3 × upper limit of normal.
Total bilirubin >1.5 × upper limit of normal, unless bilirubin rise is due to Gilbert's syndrome or of non-hepatic origin.
Estimated Creatinine clearance (CrCl) <45 mL/min.
Known clinically significant cardiovascular disease.
Ongoing active bacterial, viral, fungal, mycobacterial, parasitic, or other infection requiring systemic treatment (excluding prophylactic treatment). Past COVID-19 infection may be a risk factor.
Confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy.
Seizure disorder requiring therapy (such as steroids or anti-epileptics).
Any prior therapy with an investigational bispecific antibody targeting CD3 and CD20.
Prior treatment with chimeric antigen receptor T-cell (CAR-T) therapy within 30 days prior to first epcoritamab administration.
Eligible for curative intensive salvage therapy followed by high dose chemotherapy with HSCT rescue.
Autologous HSCT within 100 days prior to first epcoritamab administration, or any prior allogeneic HSCT or solid organ transplantation.
Active hepatitis B (DNA PCR-positive) or hepatitis C (RNA PCR-positive infection). Participants with evidence of prior HBV but who are PCR-negative are permitted in
Known human immunodeficiency virus (HIV) infection.
Exposed to live or live attenuated vaccine within 4 weeks prior to signing Informed consent form (ICF).
Pregnancy or breast feeding.
Participant is known or suspected of not being able to comply with the study protocol or has any condition for which, participation would not be in the best interest of the participant.
Contraindication to all uric acid lowering agents.

NOTE: Other protocol defined Inclusion/Exclusion criteria may apply.

Central Contact Person:

Genmab Trial Information
Telephone: +45 70202728
Email: clinicaltrials@genmab.com

Study Officials:

Study Official
Study Director
Genmab

Locations:

United States, Arizona

Arizona Mayo Clinic
[Recruiting]
Phoenix, Arizona, United States, 85054

United States, California

University of California at San Francisco
[Recruiting]
San Francisco, California, United States, 94117

United States, Colorado

Colorado Blood Cancer Institute
[Recruiting]
Denver, Colorado, United States, 80218

United States, Florida

H. Lee Moffitt Cancer Center and Research Institute
[Recruiting]
Tampa, Florida, United States, 33612

United States, Georgia

Northside Hospital- The Blood Marrow Transplant Group
[Withdrawn]
Atlanta, Georgia, United States, 30309

United States, Iowa

University of Iowa Hospital and Clinics
[Recruiting]
Iowa City, Iowa, United States, 52242

United States, Louisiana

Ochsner Medical Center
[Recruiting]
New Orleans, Louisiana, United States, 70121

United States, Michigan

University of Michigan
[Recruiting]
Ann Arbor, Michigan, United States, 48109

Barbara Ann Karmanos Cancer Institute
[Recruiting]
Detroit, Michigan, United States, 48334

United States, Nebraska

University of Nebraska Medical Center
[Recruiting]
Omaha, Nebraska, United States, 68198

United States, New Jersey

Hackensack Meridian Health
[Recruiting]
Hackensack, New Jersey, United States, 07601

United States, North Carolina

Levine Cancer institute/ Atrium Health
[Withdrawn]
Charlotte, North Carolina, United States, 28204

United States, Ohio

The Cleveland Clinic Foundation
[Recruiting]
Cleveland, Ohio, United States, 44195

United States, Oregon

OHSU Knight Cancer Institute
[Recruiting]
Portland, Oregon, United States, 97210

United States, Pennsylvania

Hillman Cancer Center
[Recruiting]
Pittsburgh, Pennsylvania, United States, 15232

United States, Rhode Island

Rhode Island Hospital
[Recruiting]
Providence, Rhode Island, United States, 02903

United States, South Carolina

Medical University of South Carolina
[Recruiting]
Charleston, South Carolina, United States, 29425

Prisma Health- Upstate
[Withdrawn]
Greenville, South Carolina, United States, 29605

United States, Texas

UT Southwestern
[Recruiting]
Dallas, Texas, United States, 75390

MD Anderson Cancer Center
[Recruiting]
Houston, Texas, United States, 77030

United States, Wisconsin

University of Wisconsin Carbone Cancer Center
[Withdrawn]
Madison, Wisconsin, United States, 53705

Australia

Monash Health
[Recruiting]
Clayton, Australia

Concord Hospital
[Recruiting]
Concord, Australia

St. Vincent Hospital
[Recruiting]
Fitzroy, Australia

Integrated Clinical Oncology Network Pty Ltd (ICON)
[Recruiting]
Herston, Australia Royal Brisbane and Women's Hospital
Herston, Australia

Royal Hobart Hospital RHH
[Recruiting]
Hobart, Australia

St. George Hospital
[Recruiting]
Kogarah, Australia

Cabrini Hospital
[Recruiting]
Malvern, Australia

Sir Charles Gairdner Hospital
[Recruiting]
Nedlands, Australia

Gold Coast Hospital
[Recruiting]
Southport, Australia

St George Westmead Hospital
[Recruiting]
Sydney, Australia

Canada

Tom Baker Cancer Care
[Recruiting]
Calgary, Canada

Toronto-Sunnybrook Regional Cancer Ctr
[Completed]
Toronto, Canada

Denmark

Rigshospitalet
[Recruiting]
Copenhagen, Denmark

Odense University Hospital
[Recruiting]
Odense, Denmark, 5000 C

Vejle Hospital
[Recruiting]
Vejle, Denmark

Finland

Helsinki University Hospital
[Recruiting]
Helsinki, Finland

Kuopio University Hospital
[Recruiting]
Kuopio, Finland

Tampere University Hospital
[Recruiting]
Tampere, Finland

France

Hopital Henri Mondor
[Recruiting]
Créteil, France

Hopital Huriez-CHRU Lille
[Withdrawn]
Lille, France

CHU Montpellier
[Recruiting]
Montpellier, France

Hospital Saint-Louis
[Recruiting]
Paris, France

Hospices Civils de Lyon Centre Hospitalier Lyon Sud
[Recruiting]
Pierre-Bénite, France

Centre Henri Becquerel
[Recruiting]
Rouen cedex, France

CHU de Tours-Hopital Bretonneau
[Recruiting]
Tours, France

Institut Gustave Roussy
[Withdrawn]
Villejuif, France

Germany

Charite - Universitaetsmedizin Berlin
[Recruiting]
Berlin, Germany

Klinik fur Innere Medizin Hamatologie and Onkologie
[Recruiting]
Berlin, Germany

Universitaetsklinikum Koeln
[Recruiting]
Cologne, Germany

Universitaetsklinikum Essen
[Recruiting]
Essen, Germany

Johannes Gutenberg University
[Recruiting]
Mainz, Germany

Der Universität Munchen Medizinische Klinik III LMU
[Recruiting]
München, Germany

Italy

Ao Ss Antonio E Biagio Alessandria
[Recruiting]
Alessandria, Italy

Policlinico S. Orsola-Ematologia LA Seragnoli
[Recruiting]
Bologna, Italy

Istituto di Candiolo- Fondazione del Piemonte per l'Oncologia
[Recruiting]
Candiolo, Italy

Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori
[Recruiting]
Meldola, Italy

IRCCS Ospedale San Raffaele
[Recruiting]
Milan, Italy

Korea, Republic of

Dong-A University Hospital
[Active, not recruiting]
Busan, Korea, Republic of

Keimyung University Dongsan Medical Center
[Active, not recruiting]
Daegu, Korea, Republic of

National Cancer Center
[Active, not recruiting]
Goyang-si, Korea, Republic of

Chonbuk National University Hospital
[Active, not recruiting]
Jeonju, Korea, Republic of

Seoul National University Bundang Hospital
[Active, not recruiting]
Seongnam-si, Korea, Republic of

Asan Medical Center
[Active, not recruiting]
Seoul, Korea, Republic of

Samsung Medical Center
[Active, not recruiting]
Seoul, Korea, Republic of

Seoul National University Hospital
[Active, not recruiting]
Seoul, Korea, Republic of

Severance Hospital, Yonsei University
[Completed]
Seoul, Korea, Republic of

Netherlands

VU University Medical Center
[Recruiting]
Amsterdam, Netherlands

Maastricht University Medical Center
[Active, not recruiting]
Maastricht, Netherlands, 6229 HX

Erasmus MC Cancer Institute
[Recruiting]
Rotterdam, Netherlands

Universitair Medisch Centrum Utrecht
[Recruiting]
Utrecht, Netherlands

Poland

Szpital Uniwersytecki nr 2 im dr. Jana Biziela
[Recruiting]
Bydgoszcz, Poland

Uniwersyteckie Centrum Kliniczne
[Recruiting]
Gdańsk, Poland

Pratia-McM
[Recruiting]
Kraków, Poland

Uniwersytet Medyczny w Lublinie
[Withdrawn]
Lublin, Poland

Wojewodzki Szpital Specjalistyczny im. Janusza Korczaka
[Recruiting]
Słupsk, Poland

Maria Sklodowska-Curie Memorial Cancer Center and Institute
[Recruiting]
Warszawa, Poland

Uniwersytecki Szpital Kliniczny im. Jana Mikulicza-Radeckiego
[Recruiting]
Wrocław, Poland

Singapore

National University Hospital
[Recruiting]
Singapore, Singapore

Singapore General Hospital
[Recruiting]
Singapore, Singapore

Spain

Hospital Germans Trias i Pujol
[Recruiting]
Badalona, Spain

Hospital Universitario Vall dHebron
[Recruiting]
Barcelona, Spain

Institut Catala de Oncologia
[Recruiting]
Barcelona, Spain

Hospital Universitario Fundacin Jimnez Daz
[Recruiting]
Madrid, Spain

Spain, Navarra

Clinica Universidad de Navarra
[Recruiting]
Pamplona, Navarra, Spain, 31008

Sweden

Skåne University Hospital
[Recruiting]
Lund, Sweden

Karolinska University Hospital Huddinge
[Recruiting]
Stockholm, Sweden

Akademiska sjukhuset Uppsala University Hospital
[Recruiting]
Uppsala, Sweden

United Kingdom

University Hospital of Wales
[Withdrawn]
Cardiff, United Kingdom

United Kingdom

The Christie NHS Foundation Trust
[Recruiting]
Manchester, United Kingdom

Plymouth University School of Medicine- Derriford Hospital
[Recruiting]
Plymouth, United Kingdom

University Hospital Southampton NHS Foundation Trust
[Active, not recruiting]
Southampton, United Kingdom

Royal Marsden NHS Foundation Trust
[Recruiting]
Sutton, United Kingdom